Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nonabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 known ✓ | P34972 | 4/20 | 0.31 |
| ▸ | CNR1 known ✓ | P21554 | 3/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.31 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.31 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.31 |
| ▸ | TRPV2 | Q9Y5S1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17414514 | 0.99 | KDR (0.33) | KDRCNR2CNR1TRPA1CYP1A1 | |
| SCHEMBL15995031 | 0.86 | — | — | |
| SCHEMBL9285694 | 0.77 | CNR2 (0.45) | CNR2CNR1TRPA1CYP1A1CYP1A2 | |
| SCHEMBL11880805 | 0.76 | KDR (0.36) | KDRCNR2CNR1 | |
| Hydrochloric Acid SCHEMBL11814036 | 0.76 | CNR2 (0.42) | CNR2CNR1TRPA1CYP1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL11812153 | 0.76 | CNR2 (0.45) | CNR2CNR1TRPA1CYP1A1CYP1A2 | |
| SCHEMBL31545470 | 0.75 | KDR (0.38) | KDRCNR2CNR1 | |
| SCHEMBL31545447 | 0.72 | KDR (0.36) | KDRCNR2CNR1 | |
| SCHEMBL22891912 | 0.71 | — | — | |
| SCHEMBL31545506 | 0.71 | CNR2 (0.64) | CNR2CNR1TRPA1CYP1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| CN-116868895-A | Method for calculating tissue culture and rapid propagation of gentiana kusnezoffii plant | 西藏自治区高原生物研究所 | 2023-10-13 | — | — | CN | claimed |
| CN-114009515-A | Processing technology of tea green granular yellow tea in non-albino period of tea trees | 贵州省正安县乐茗香生态有机茶业有限公司 | 2022-02-08 | — | — | CN | claimed |
| US-20150313868-A1 | USE OF CANNABINOIDS AND TERPENES FOR TREATMENT OF ORGANOPHOSPHATE AND CARBAMATE TOXICITY | KOTZKER CONSULTING LLC | 2015-11-05 | — | — | US | claimed |
| EP-2934512-A1 | USE OF CANNABINOIDS AND TERPENES FOR TREATMENT OF ORGANOPHOSPHATE AND CARBAMATE TOXICITY | Kotzker Consulting LLC (US) | 2015-10-28 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2014100231-A1 | USE OF CANNABINOIDS AND TERPENES FOR TREATMENT OF ORGANOPHOSPHATE AND CARBAMATE TOXICITY | KOTZKER CONSULTING LLC (US) | 2014-06-26 | — | — | WO | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20250361252-A1 | APOMORPHINE PRODRUGS AND USES THEREOF | EVER NEURO PHARMA GMBH (AT) | 2025-11-27 | — | — | US | disclosed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | CNR2 204/4885CNR1 221/4885KDR 4730/4885 |
| US-20250361252-A1 | APOMORPHINE PRODRUGS AND USES THEREOF | THOP1, MC1R, PAH | CNR2 1262/4885CNR1 869/4885KDR 2718/4885 |
| US-20150313868-A1 | USE OF CANNABINOIDS AND TERPENES FOR TREATMENT OF ORGANOPHOSPHATE AND CARBAMATE TOXICITY | BCHE, ACHE, CNR1 | CNR2 4/4885CNR1 3/4885KDR 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.